Cel Sci (CVM) Accumulated Expenses (2010 - 2026)
Cel Sci (CVM) posted Accumulated Expenses of $404220.0 for Q1 2026, down 6.1% sequentially from $430460.0 in Q4 2025, and down 31.9% YoY from $593551.0 in Q1 2025.
Cel Sci (CVM) Accumulated Expenses (2010 - 2026) Analysis & Trends
Cel Sci has reported Accumulated Expenses for 16 years, with the latest figure at $404220.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 31.9% year-over-year to $404220.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $404220.0 (down 31.9% YoY) and the FY2025 annual result came in at $711820.0, up 25.75% from the prior year.
- Accumulated Expenses slipped to $404220.0 in Q1 2026 per CVM's latest filing, from $430460.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1.3 million in Q2 2024 and troughed at $404220.0 in Q1 2026.
- A 5-year average of $837060.1 and a median of $842492.0 in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 103.9% in 2022, then tumbled 62.61% in 2025.
- Over 5 years, Accumulated Expenses stood at $800838.0 in 2022, then advanced by 23.08% to $985657.0 in 2023, then sank by 36.94% to $621601.0 in 2024, then plunged by 30.75% to $430460.0 in 2025, then decreased by 6.1% to $404220.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $404220.0, $430460.0, and $711820.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 404,220.00 |
| Dec 31, 2025 | 430,460.00 |
| Sep 30, 2025 | 711,820.00 |
| Jun 30, 2025 | 475,602.00 |
| Mar 31, 2025 | 593,551.00 |
| Dec 31, 2024 | 621,601.00 |
| Sep 30, 2024 | 566,042.00 |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 985,657.00 |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 800,838.00 |
| Sep 30, 2022 | 842,492.00 |
| Jun 30, 2022 | 992,945.00 |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 899,901.00 |
| Sep 30, 2021 | 859,216.00 |
| Jun 30, 2021 | 868,443.00 |